Solid Tumors Clinical Trials in Baltimore, Maryland

6 studies are recruiting for solid tumors in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MedStar Franklin Square Medical Center ( Site 0046), Baltimore, Maryland

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

   This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Johns Hopkins Hospital, Baltimore, Maryland

   Locations

   58 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07492680 on ClinicalTrials.gov

3. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

   The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Baltimore, Maryland

   Locations

   25 in total

   Run by

   Arcus Biosciences, Inc.

   See if you can join NCT05536141 on ClinicalTrials.gov

4. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   John Hopkins University, Baltimore, Maryland

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

5. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

   The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

   Stage

   Phase 2

   Ages

   8 and older

   Site

   The John Hopkins Hospital, Baltimore, Maryland

   Locations

   70 in total

   Run by

   Fore Biotherapeutics

   See if you can join NCT05503797 on ClinicalTrials.gov

6. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

   This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland

   Locations

   34 in total

   Run by

   Incyte Corporation

   See if you can join NCT06179160 on ClinicalTrials.gov